# CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer

> **NCT05143151** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen University General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Pancreatic Carcinoma

## Interventions

- **BIOLOGICAL:** CD276 CAR-T cells

## Key facts

- **NCT ID:** NCT05143151
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2024-06
- **Final completion:** 2024-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143151, "CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05143151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*